83526-55-0

Basic information

• Product Name: (R)-1-O-octadecyl-3-(p-toluenesulfonyl)-glycerol
• Synonyms: (R)-1-O-octadecyl-3-(p-toluenesulfonyl)-glycerol
• CAS NO: 83526-55-0
• Molecular Weight: 498.768
• Mol File: 83526-55-0.mol

Chemical Properties

• CAS DataBase Reference: (R)-1-O-octadecyl-3-(p-toluenesulfonyl)-glycerol(CAS DataBase Reference)
• NIST Chemistry Reference: (R)-1-O-octadecyl-3-(p-toluenesulfonyl)-glycerol(83526-55-0)
• EPA Substance Registry System: (R)-1-O-octadecyl-3-(p-toluenesulfonyl)-glycerol(83526-55-0)

Safety Data

• Hazardous Substances Data: 83526-55-0(Hazardous Substances Data)

Upstream product

• 6129-13-1 batyl alcohol 
• 98-59-9 p-toluenesulfonyl chloride 
• 112-92-5 1-octadecanol 
• 113826-06-5 (R)-glycidyl tosylate 
• 83526-60-7 2-O-Acetyl-1-O-benzyl-3-O-octadecyl-sn-glycerin 
• 83526-52-7 3-O-Octadecyl-2-O-p-toluolsulfonyl-sn-glycerin 
• 83526-54-9 3-O-Octadecyl-1-O-p-toluolsulfonyl-sn-glycerin 
• 83537-01-3 (-)-1-O-octadecyl-2-O-acetyl-sn-glycerol 
• 83526-56-1 (S)-1,2-Epoxy-3-(octadecyloxy)propan 
• 83526-51-6 3-O-Octadecyl-2-O-p-toluolsulfonyl-3-O-trityl-sn-glycerin 
• 83526-50-5 3-O-Octadecyl-1,2-di-O-p-toluolsulfonyl-sn-glycerin 
• 80707-96-6 Ro 15-4454 
• 83526-57-2 (S)-1-(benzyloxy)-3-(octadecyloxy)propan-2-ol 
• 83167-57-1 3-O-Benzyl-1-O-octadecyl-sn-glycerol 

Downstream Products

• 80483-86-9 2-O-Benzyl-1-O-octadecyl-sn-glycero-3-phosphorylcholin 
• 80707-93-3 (S)-1-O-octadecyl-2-O-benzyl-glycerol 
• 74430-89-0 Lyso-platelet-activating factor (C₁₈) 
• 918946-93-7 Phosphoric acid (R)-2-benzyloxy-3-octadecyloxy-propyl ester (S)-2,2-dimethyl-[1,3]dioxolan-4-ylmethyl ester methyl ester 
• 1026554-06-2 Phosphoric acid (R)-2-benzyloxy-3-octadecyloxy-propyl ester (S)-2,3-dihydroxy-propyl ester 
• 871693-93-5 (R)-1-O-octadecyl-2-O-benzyl-3-(p-toluenesulfonyl)glycerol 

Relevant articles and documents

Synthesis and biophysical characterization of chlorambucil anticancer ether lipid prodrugs

The synthesis and biophysical characterization of four prodrug ether phospholipid conjugates are described. The lipids are prepared from the anticancer drug chlorambucil and have C16 and C18 ether chains with phosphatidylcholine or phosphatidylglycerol he

Synthesis and biological activity of anticancer ether lipids that are specifically released by phospholipase A2 in tumor tissue

The clinical use of anticancer lipids is severely limited by their ability to cause lysis of red blood cells prohibiting intravenous injection. Novel delivery systems are therefore required in order to develop anticancer ether lipids (AELs) into clinicall